Keyword Analysis & Research: turning point therapeutics


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
turning point therapeutics1.110.630191626
turning0.9716524677
point0.870.851605
therapeutics0.540.311105912

Keyword Research: People who searched turning point therapeutics also searched

Keyword CPC PCC Volume Score
turning point therapeutics0.730.9305129
turning point therapeutics stock0.840.6888371
turning point therapeutics bms1.340.945363
turning point therapeutics pipeline1.580.9969166
turning point therapeutics acquisition1.93133464
turning point therapeutics careers1.160.5734269
turning point therapeutics location1.630.374942
turning point therapeutics ceo0.360.6712513
turning point therapeutics logo1.710.7889652
turning point therapeutics news1.870.2860028
turning point therapeutics repotrectinib1.890.4866731
turning point therapeutics website0.150.57532
turning point therapeutics inc1.721796962
turning point therapeutics and bms0.091588490

Search Results related to turning point therapeutics on Search Engine

  • Bristol Myers Squibb to Acquire Turning Point Therapeutics, a …

    bms.com

    https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-to-Acquire-Turning-Point-Therapeutics-a-Leading-Precision-Oncology-Company/default.aspx

    WEBJun 3, 2022 · Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis. Turning Point Therapeutics’ lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting the ROS1 ...

    DA: 97 PA: 96 MOZ Rank: 64

  • Bristol Myers Squibb Completes Acquisition of Turning Point

    bms.com

    https://news.bms.com/news/details/2022/Bristol-Myers-Squibb-Completes-Acquisition-of-Turning-Point-Therapeutics-Expanding-Precision-Oncology-Portfolio/default.aspx

    WEB08/17/2022. Category: Corporate/Financial News. NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.

    DA: 88 PA: 28 MOZ Rank: 92

  • Bristol Myers boosts cancer drug portfolio with $4.1 billion Turning

    reuters.com

    https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-buy-turning-point-41-bln-2022-06-03/

    WEBJune 3 (Reuters) - Bristol Myers Squibb Co (BMY.N) said on Friday it will acquire drug developer Turning Point Therapeutics Inc (TPTX.O) for $4.1 billion in cash to help bolster its arsenal...

    DA: 32 PA: 5 MOZ Rank: 92

  • Turning Point Therapeutics Granted Breakthrough Therapy

    globenewswire.com

    https://www.globenewswire.com/news-release/2021/10/04/2307947/0/en/Turning-Point-Therapeutics-Granted-Breakthrough-Therapy-Designation-for-Repotrectinib-Treatment-in-Patients-with-NTRK-Positive-TKI-Pretreated-Advanced-Solid-Tumors.html

    WEBSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

    DA: 40 PA: 49 MOZ Rank: 20

  • Turning Point Therapeutics Announces Initial Clinical Data

    globenewswire.com

    https://www.globenewswire.com/news-release/2021/04/05/2204507/0/en/Turning-Point-Therapeutics-Announces-Initial-Clinical-Data-From-Phase-1-2-SWORD-1-Study-of-RET-Inhibitor-TPX-0046.html

    WEBSAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

    DA: 47 PA: 75 MOZ Rank: 86

  • Turning Point Therapeutics Announces Positive Topline Data

    globenewswire.com

    https://www.globenewswire.com/news-release/2022/04/12/2421462/0/en/Turning-Point-Therapeutics-Announces-Positive-Topline-Data-by-Blinded-Independent-Central-Review-for-Repotrectinib-Across-All-ROS1-Positive-NSCLC-Cohorts-of-Phase-1-2-TRIDENT-1-Stu.html

    WEBSAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target...

    DA: 29 PA: 81 MOZ Rank: 45

  • Turning Point Therapeutics Granted Breakthrough Therapy …

    yahoo.com

    https://finance.yahoo.com/news/turning-point-therapeutics-granted-breakthrough-123000028.html

    WEBSAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for...

    DA: 39 PA: 24 MOZ Rank: 69

  • Turning Point Therapeutics Granted Breakthrough Therapy …

    yahoo.com

    https://finance.yahoo.com/news/turning-point-therapeutics-granted-breakthrough-130000048.html

    WEBSAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...

    DA: 94 PA: 14 MOZ Rank: 72

  • Bristol Myers Squibb Completes Acquisition of Turning Point

    nasdaq.com

    https://www.nasdaq.com/press-release/bristol-myers-squibb-completes-acquisition-of-turning-point-therapeutics-expanding

    WEBAug 17, 2022 8:31am EDT. NEW YORK -- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc....

    DA: 32 PA: 41 MOZ Rank: 4

  • Biotech buyout: San Diego's Turning Point Therapeutics sells to …

    sandiegouniontribune.com

    https://www.sandiegouniontribune.com/business/story/2022-06-03/biotech-buyout-san-diegos-turning-point-therapeutics-sells-to-bristol-myers-squibb-for-4-1-billion

    WEBJun 3, 2022 · Bristol Myers Squibb has inked a deal to buy San Diego’s Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant’s presence in precision cancer treatments....

    DA: 99 PA: 14 MOZ Rank: 39